NCT04094961View on ClinicalTrials.gov

Ixazomib + Pomalidomide + Dexamethasone In MM

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

September 18, 2019

Primary Completion Date

June 1, 2025

Study Completion Date

January 1, 2027

Conditions

Multiple MyelomaMultiple Myeloma in Relapse

Interventions

DRUG

Ixazomib

Oral, administered four times per cycle

DRUG

Pomalidomide

Oral, administered 14 times per cycle

DRUG

Dexamethasone

Oral, fixed dose administered 8 times per cycle

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Takeda

INDUSTRY

lead

Omar Nadeem, MD

OTHER

NCT04094961 - Ixazomib + Pomalidomide + Dexamethasone In MM | Biotech Hunter | Biotech Hunter